This fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID.

Pfizer's COVID-19 vaccine for children under five may lose FDA authorization, leading to potential supply shortages. Modern ...

Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

And the Novavax Covid-19 vaccine that just got emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) is certainly new. It’s new in that it’s not completely new.

Lots of people are hearing about Novavax, the fourth COVID vaccine option in the U.S., for the first time, but it’s been authorized for use as a primary vaccine series since early 2022.

Newfangled COVID-19 vaccines have left many people yearning for an old-school alternative. The one from Novavax could fit that bill.

In this Feb. 26, 2022 file photo a kidney dish with syringes containing the Novavax COVID-19 vaccine sits in a refrigerator ready for use at a vaccination center in Prisdorf, Germany, Feb. 26, 2022.

After more than a year with two types of Covid-19 vaccines in use in the United States, another will be up for consideration by the US Food and Drug Administration next week.

Novavax COVID vaccine shows strong efficacy The biotechnology company announced Monday that its stage three clinical trial showed overall efficacy of 90.4% against COVID-19.

Vaccine advisers to the US Food and Drug Administration decided Tuesday that authorizing Novavax’s Covid-19 vaccine – which uses different technology from the three vaccines currently in use ...

Novavax’s recent application for licensing its Covid-19 vaccine in Australia, Canada, and the UK hasn’t gained much traction in the US media. This is odd, given that the vaccine could not only ...

Novavax has been working on developing vaccines for more than three decades, but hasn’t brought one to market. The company’s COVID-19 vaccine work is partly funded by the U.S. government.